In these earlier studies which employed HER2-overexpressing human subcutaneous breast cancer xenografts, combined treatment with Trast plus BVZ resulted in significant reduction in tumor volume compared to Trast alone6. The gene discussed is ERBB2; the disease is neoplasm.